MedPath

comparison between Intralesional injection of 2% zinc sulfate and intralesional glucantime in treatment of cutaneous leishmaniasis.

Phase 1
Recruiting
Conditions
leishmaniasis
Skin - Dermatological conditions
Registration Number
ACTRN12609000115235
Lead Sponsor
Kerman medical university
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

the patients with urban cutaneous leishmaniasis with the onset of lower than 3 months

Exclusion Criteria

taking any treatment of leishmaniasis within last month

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
size of induration is measured with a transparent paper by an independed observer who was blind to the treat options['size of induration' is measured 'every 2 weeks until 10 weeks ( end of treatment); 2weeks after end of treatment and 3 months after end of treatment]
Secondary Outcome Measures
NameTimeMethod
smear for leishmaniasis[smear is taken at the end of treatment; 2weeks and 3 months after the end of treatment]
© Copyright 2025. All Rights Reserved by MedPath